Biohaven Pharma

225 articles with Biohaven Pharma

• Biohaven' BHV-0223 Is Granted Orphan Drug Designation In The Treatment Of Amyotrophic Lateral Sclerosis

  12/9/2016

• Biohaven Announces Orphan Drug Designation Request Granted For Bhv-0223 In The Treatment Of Amyotrophic Lateral Sclerosis ("Als")

  12/8/2016

• Biohaven Secures $80 Million In Oversubscribed Private Financing To Advance Phase 3 Clinical Trials

  11/1/2016

• Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment

  10/3/2016

• Biohaven Commences Clinical Testing Of BHV-4157

  7/20/2016